Search results
Results from the WOW.Com Content Network
Enzyme potentiated desensitization (EPD), is a treatment for allergies developed in the 1960s by Dr. Leonard M. McEwen in the United Kingdom.EPD uses much lower doses of antigens than conventional desensitization treatment paired with the enzyme β-glucuronidase.
One of the most prevalent forms of adverse drug reactions is cutaneous reactions, [1] with drug-induced urticaria ranking as the second most common type, preceded by drug-induced exanthems. [2] Urticaria, commonly known as hives , manifests as weals, itching, burning, redness, swelling, and angioedema —a rapid swelling of lower skin layers ...
Allergen immunotherapy, also known as desensitization or hypo-sensitization, is a medical treatment for environmental allergies (such as insect bites) and asthma. [1] [2] Immunotherapy involves exposing people to larger and larger amounts of allergens in an attempt to change the immune system's response.
A drug allergy is an allergy to a drug, most commonly a medication, and is a form of adverse drug reaction. Medical attention should be sought immediately if an allergic reaction is suspected. An allergic reaction will not occur on the first exposure to a substance.
Pseudo-allergic reactions in which a drug directly stimulates mast cells, basophils, and/or eosinophils to release pro-allergic mediators (e.g. histamine); Type I , Type II , and Type III hypersensitivity reactions of the adaptive immune system mediated by IgE , IgG , and/or IgM antibodies; and
The symptoms of DRESS syndrome usually begin 2 to 6 weeks but uncommonly up to 8–16 weeks after exposure to an offending drug. Symptoms generally include fever, an often itchy rash which may be morbilliform or consist mainly of macules or plaques, facial edema (i.e. swelling, which is a hallmark of the disease), enlarged and sometimes painful lymph nodes, and other symptoms due to ...
In conjunction with achieving the practical goal to investigate the applicability of the anti-IgE therapy as a potential treatment for allergic diseases, the many corporate-sponsored clinical trials of TNX-901 and omalizumab on asthma, allergic rhinitis, peanut allergy, chronic idiopathic urticaria, atopic dermatitis, and other allergic ...
The goals in this area are finding a cure for HIV-infected individuals; developing preventive strategies, including vaccines and treatment as prevention; developing therapeutic strategies for preventing and treating co-infections such as TB and hepatitis C in HIV-infected individuals; and addressing the long-term consequences of HIV treatment.